BLS Pharmaceuticals Limited (ASX: BLS) - Share Price
Current share price for BLS : $0.880 0.02 (2.33%)+
BLS Pharmaceuticals Limited (BLS, formerly Bioxyne Limited) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian pharmaceutical company focused on the development manufacture and commercialization of medicines final patient dosage forms and active pharmaceutical ingredients.
BLS General Information +
| ASX Code | BLS |
| Website | http://www.blspharma.com |
| Industry/Sector | Personal Products |
| Market Cap ($M) | 202 |
| BLS Share Price | $0.880 |
| Day High | $0.880 |
| Day Low | $0.845 |
| Last Close | $0.860 |
| BLS Share Price Movement | $0.02 ( 2.33% ) |
Prices as at 16:35, 6 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
BLS Pharmaceuticals Limited (BLS) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from BLS Pharmaceuticals Limited (BLS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
BLS Pharmaceuticals Limited (BLS) price-sensitive announcements
BLS - BLS Pharmaceuticals Investor Webinar Presentation
BLS Pharmaceuticals Limited, through its subsidiary Breathe Life Sciences, is a globally r
BLS Pharmaceuticals Limited (BLS)
30 Jul 2026 | 8:57 AM
30 Jul 2026 | 8:57 AM
BLS - Quarterly Activities/Appendix 4C Cash Flow Report
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, reported significant financial and
BLS Pharmaceuticals Limited (BLS)
27 Jul 2026 | 8:52 AM
27 Jul 2026 | 8:52 AM
BLS Pharmaceuticals Limited (BLS) Recent ASX Announcements
BLS Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | $4.90 | $0.20 | -450.00% | 9.60 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.41 | -$0.10 | -57.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$1.87 | -$0.10 | 250.00% | 0.00 | 0.00 | 0.00% | 0.0% |
BLS Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| BLS Pharmaceuticals Limited (BLS) | $195M | -4.5000 | 0.0000 | 0.0000 | 404.7619 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
BLS Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 2.21 | 409.50 | 150.90 | 0.00 |
| Market | 0.32 | 13.00 | 1.15 | 0.61 |
| Sector | 0.00 | 167.50 | 0.96 | 0.00 |
BLS Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Samuel Watson | Chief Executive Officer, Managing Director | 19 May 2023 |
| Mr Jason Hine | Executive Director | 19 May 2023 |
| Mr Edward Myer | Non-Executive Director | 3 Jun 2026 |
| Mr Anthony (Tony) Peng Ho | Non-Executive Director, Non-Executive Chairman | 30 Oct 2012 |
BLS Pharmaceuticals Limited (BLS) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 May 2026 | HO, Anthony (Tony) | Buy | Indirect Shares | 5,000,000 | $0.020 | $100,000.000 |
| 12 May 2026 | HO, Anthony (Tony) | Exercise | Options | 5,000,000 | $0.020 | $100,000.000 |
| 19 Mar 2026 | WATSON, Samuel | Buy | Indirect Shares | 1,800,000 | $0.050 | $90,000.000 |
See all changes in directors' interest & trades for BLS Pharmaceuticals Limited (BLS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
BLS Management
| Name | Position |
|---|---|
| Guy Adrian Robertson | Company Secretary |
BLS Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in BLS Pharmaceuticals Limited (BLS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 576,268,527 (26.53%) | BREATHE INTERNATIONAL LIMITED |
| 132,488,966 (6.10%) | Ian Edward Owles |
| 130,821,636 (6.02%) | BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> |
BLS Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 29 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
